Company profile
Narval Bio company profile
Narval develops next-generation of antibody-like drugs using macrocyclic synthetic proteins that mimicthe activity of antibodies and can be delivered through mucosal tissues for localized treatment and non-systemic delivery. Our Antibody Mimetic Proteins, or AMP for short, are developed by fusing CDR3 regions of a single domain shark antibodies toa conoprotein scaffold from a sea snail, and we optimize their capabilities using AI and ML algorithms. Narval’s AMPs offer a breakthrough solution for fast, accessible, and deployable therapeutics in areas like pandemics, emergency outbreaks, biodefense, animal health, and agricultural biosecurity.
Business identity
- Website
- https://narvalbio.co/
- Contact email
- [email protected]
- Phone number
- (+52) 33 2659 8473
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 00001-00010 employees
- Founded
- 2024-02-12
Headquarters
- Headquarters
- San Jacinto Chilateca, Oaxaca, Mexico
- Country code
- MX
- Continent
- North America